The main objectives of the study were to further investigate the clinical importance of B1R as a biomarker and therapeutic target for PCa using molecular profiling of relevant in vitro human PCa cell lines and clinical samples, and to evaluate the theranostic potential of a new radiopeptide targeting B1R for PCa detection and therapy. Here, BDKRB1 is linked to posterior cortical atrophy.